Biotech

Latest Articles

Basilea scores $268M BARDA funding for antifungals, anti-biotics

.Basilea Pharmaceutica's work developing brand new antifungals has actually acquired a significant i...

Capricor markets Europe liberties to late-stage DMD treatment for $35M

.Having already gathered up the U.S. liberties to Capricor Therapies' late-stage Duchenne muscle dys...

FDA fragments adcomm for Applied's uncommon illness medicine

.After pushing back the choice date for Applied Therapies' metabolic problem medication govorestat, ...

Novo inks $600M NanoVation offer to research hereditary medicines ex-liver

.Novo Nordisk is actually continuing its own push in to hereditary medicines, accepting compensate N...

Innovent web links cytokine to colorectal cancer reactions

.Innovent Biologics has actually created the scenario that its own checkpoint inhibitor-cytokine com...

Merck, Daiichi ADC hits target in period 3 bronchi cancer research study

.A stage 3 test of Daiichi Sankyo and Merck &amp Co.'s HER3-directed antibody-drug conjugate (ADC) h...

Rakovina deepens AI focus along with collab to decide on cancer aim ats

.Five months after Rakovina Therapeutics rotated towards artificial intelligence, the cancer-focused...

Ascendis' dwarfism drug hits in period 3, intimidates BioMarin

.Ascendis Pharma has actually emerged as a potential danger to BioMarin's Voxzogo, stating phase 3 d...

Despite ph. 3 overlook, Alkeus views pathway ahead for eye health condition possession

.Though Alkeus Pharmaceuticals' oral eye ailment possession neglected to substantially decrease geog...

Kairos goes social along with $6M IPO to finance tests of cancer cells drug

.With a trio of biotechs hitting the Nasdaq on Friday, it was actually quick and easy to skip a smal...

Vaccine and also Keytruda combo effective in squamous cell cancer

.Immune system checkpoint preventions are actually the superheroes of cancer cells therapy. Medicine...

Cue Biopharma mark time J&ampJ vet as CBO-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our summary of considerable leadership hirings, shooting...

Regeneron's Opdualag rival presents 57% response fee

.Regeneron is back with lasting consequence for its LAG-3 prevention as well as PD-1 inhibitor combi...

AstraZeneca articles records on internal rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared a very early check out the functionality of its in-house antibody-d...

iTeos- GSK's TIGIT star reveals meaningful renovation

.After revealing a stage 3 launch based on favorable midstage results, iTeos as well as GSK are last...

More collaborative FDA can accelerate rare condition R&ampD: document

.The FDA must be actually more available and also joint to let loose a rise in commendations of rare...

Zenas, MBX, Bicara scalp to Nasdaq in scorching day for biotech IPOs

.It's an unusually active Friday for biotech IPOs, along with Zenas BioPharma, MBX as well as Bicara...

Atea's COVID antiviral neglects to halt hospital stays in period 3

.Atea Pharmaceuticals' antiviral has actually failed an additional COVID-19 test, but the biotech st...

Neurocrine's offer to conserve schizophrenia prospect stops working

.Neurocrine Biosciences' schizophrenia program pivot has fallen short. The biotech was actually not ...

Sanofi spends $110M upfront for late-stage radioligand therapy

.Sanofi has made an overdue entrance to the radioligand gathering, spending one hundred thousand eur...